Omica applies AI biomarker screening to routine biopsies across a network of pathology laboratories in Latin America, identifying patients eligible for targeted therapies.
The Diagnostic Gap
Most cancer patients never receive the biomarker testing required for targeted therapies.
Omica screens routine H&E slides at diagnosis, flagging suspected biomarker-positive cases for immediate reflex confirmation before first-line therapy begins.
Capabilities
We partner with biopharma to deploy AI screening in hospital pathology labs, reflexing biomarker-suspect cases to confirmatory testing and clinical trial enrollment.
Explore Diagnostics
Tissue specimens matched with digital pathology, multi-omic sequencing, and longitudinal outcomes: biological ground truth to train robust cancer models.
Explore BiobankPRISMA
PRISMA combines vendor-neutral whole-slide viewing, case management, and on-slide AI analysis directly in the hospital laboratory.
Pathologists review routine cases on-premise while embedded models flag suspected biomarker signatures, triggering reflex confirmatory testing without administrative burden.
Discover PRISMAThe Closed Loop
Pathology AI fails when trained on isolated datasets and deployed into foreign clinical environments. Omica unifies tissue characterization, model training, and hospital deployment in a single regional network.
We link physical biopsy blocks with high-resolution whole-slide imaging, genomic sequencing, and longitudinal patient outcomes.
We train predictive models against verified biological ground truth from populations absent from standard reference databases.
We deliver validated screening models directly into hospital laboratories via PRISMA, reflexing cases during standard diagnostic sign-out.
Research
